There are plenty of ASX shares out there for investors to choose from.
To narrow things down, let's see what analysts are saying about three popular shares, courtesy of The Bull. Here's what they are recommending:
Image source: Getty Images
Orica Ltd (ASX: ORI)
The team at Bell Potter is bullish on this commercial explosives company and has named it as a buy this week.
The broker has been impressed with its transformation and highlights its cyclical leverage and structural growth as reasons to invest. It explains:
Orica is a mining and infrastructure solutions provider. Orica's transformation is gaining traction, with diversified growth across blasting solutions, speciality mining chemicals and digital solutions. Earnings before interest and tax (EBIT) of $992 million in fiscal year 2025 were up 23 per cent on the prior corresponding period. The significant rise was underpinned by strong demand for sodium cyanide, increased digital product uptake and solid execution across manufacturing assets. Management has upgraded its medium term EBIT target, and an additional $100 million buy-back program is underway. Orica offers a compelling blend of cyclical leverage and structural growth.
Origin Energy Ltd (ASX: ORG)
Over at DP Wealth Advisory, its team has named this energy giant as a hold this week.
While it sees positives, such as its investment in Octopus Energy, it isn't enough for a more bullish recommendation. DP Wealth Advisory said:
This energy provider delivers services to more than 4 million Australian customers. It's also a significant exporter of LNG through its stake in APLNG (Australia Pacific LNG). A positive for Origin is its 22.7 per cent interest in Octopus Energy in the UK and, in particular, the Kraken Technologies platform. A spin-off of Kraken into a stand-alone entity should add value to ORG.
Pro Medicus Ltd (ASX: PME)
Analysts at Fairmont Equities aren't buyers of this health imaging technology company's shares despite their heavy decline. The equities firm has named Pro Medicus shares as a sell this week.
Fairmont Equities appears concerned that the decline could continue if sentiment doesn't improve in the near term. It said:
This medical technology business is one we have successfully traded on several occasions during the past few years. However, since mid-2025, we have stayed away from expensive technology companies, such as PME, due to negative market sentiment. On February 12, 2026, the company announced revenue from ordinary activities of $124.8 million in the first half of 2026, an increase of 28.4 per cent. Underlying net profit of $67.3 million was up 29.7 per cent.
However the share price was severely punished following the result. Perhaps, the result fell short of market expectations. The shares have fallen from $330.48 on July 17, 2025 to trade at $132.86 on February 12, 2026. The shares may fall further if sentiment doesn't improve.
